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Abstract
Glucose transport and consumption are increased in
tumors, and this is considered a diagnostic index of
malignancy. However, there is recent evidence that
carcinoma-associated stromal cells are capable of aero-
bic metabolism with low glucose consumption, at least
partly because of their efficient vascular supply. In
the present study, using dynamic contrast-enhanced
magnetic resonance imaging and [F-18]fluorodeoxyglu-
cose (FDG) positron emission tomography (PET), we
mapped in vivo the vascular supply and glucose metab-
olism in syngeneic experimental models of carcinoma
and mesenchymal tumor. We found that in both tumor
histotypes, regions with high vascular perfusion exhib-
ited a significantly lower FDG uptake. This reciprocity
was more conspicuous in carcinomas than in mesen-
chymal tumors, and regions with a high-vascular/low-
FDG uptake pattern roughly overlapped with a stromal
capsule and intratumoral large connectival septa. Ac-
cordingly, mesenchymal tumors exhibited a higher
vascular perfusion and a lower FDG uptake than car-
cinomas. Thus, we provide in vivo evidence of vascular/
metabolic reciprocity between epithelial and mesen-
chymal histotypes in tumors, suggesting a new intrigu-
ing aspect of epithelial–stromal interaction. Our results
suggests that FDG-PET–based clinical analysis can un-
derestimate the malignity or tumor extension of carcino-
mas exhibiting any trait of ‘‘mesenchymalization’’ such
as desmoplasia or epithelial–mesenchymal transition.
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Introduction
Glucose transport and consumption are increased in tumors,
and this is considered a diagnostic index of malignancy [1–4].
Based on this assumption, [F-18]fluorodeoxyglucose (FDG)
positron emission tomography (PET) is being used in
clinical practice for tumor diagnosis and volume delineation
before therapeutic treatment [5–9]. However, recent work has
demonstrated differential glucose absorption between epithe-
lial and stromal compartments within carcinomas, revealing the
synergistic complementarities of their metabolism [10]. Cancer
cells have an inherent tendency for anaerobic glycolysis
[11,12], which is massively enhanced by a lack of adequate
blood supply [13–16] and leads to abnormal glucose consump-
tion and lactate extrusion. Conversely, tumor-associated stro-
mal cells are capable of aerobic metabolism with low glucose
consumption, and it has been proposed that they could clear
and recycle the lactate produced by the anaerobic metabolism
of cancer cells [10]. This is a further intriguing aspect of
epithelial–stromal interaction and is consistent with the high
angiogenic potential of tumor-associated reactive stromal cells
[17,18], which provide mesenchymal compartments with ade-
quate blood supply [19]. Thus, we hypothesized that the combi-
nation of FDG-PET and dynamic contrast-enhanced magnetic
resonance imaging (DCE-MRI) can discriminate in vivo the
epithelial and stromal compartments in carcinomas.
Furthermore, the anatomic distinction between epithelial
and mesenchymal compartments in carcinomas, particularly
of the breast, is an aspect of tumor biology that is currently
undergoing revision. Not uncommonly, carcinomas reveal
colocalization of mesenchymal and epithelial markers or exhibit
abnormally developed stroma (desmoplasia) [20]; in some
cases, they can even transdifferentiate into carcinosarcomas
or monophasic sarcomas, usually proving malignant in either
case [21,22]. The ‘‘mesenchymalization’’ of carcinomas has
recently been described also in transgenic murine models of
HER-2/neu carcinomas [23,24] and represents a possible
mode of tumor recurrence [25]. This experimental evidence
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prompts speculation that the capacity to generate mesen-
chymal tumors is inherent in carcinomas and that they can
arise autonomously if the epithelium is attacked, for instance
after therapeutic treatment [26]. In line with this evidence, we
have recently established a HER-2/neu–negative mesen-
chymal cell lineage, called A17, from a HER-2/neu transgenic
mammary tumor, a subcutaneous injection (into syngeneic
mice) of which led to the development of mesenchymal tu-
mors [27]. If the extent of glucose absorption in carcinomas
results from the relative contribution of the epithelial and stro-
mal compartments, it is reasonable to suppose that it is af-
fected by any formofmesenchymalization and, in particular, by
complete transdifferentiation toward a sarcomatoid phenotype.
To investigate these hypothesis, we used FDG-PET [1]
and DCE-MRI [28] to comparatively map, in vivo, the glucose
consumption and vascular perfusion of previously described
[27] syngeneic murine models of spontaneous and trans-
planted (BB1) carcinoma and carcinoma-derived sarcoma (A17).
Materials and Methods
Tumor Models
The spontaneous and transplanted tumors used in this
study have already been described. Briefly, spontaneous
tumors were mammary carcinomas that arose in FVB mice
(line 233) that were transgenic for the activated isoform of
rat HER-2/neu (NeuNT ) oncogene (FVB/neuT233) and were
purchased from Charles River Laboratories (Calco, Italy).
The A17 and BB1 cell lines were established from sponta-
neous HER-2/neu transgenic tumors. Subcutaneous injec-
tion of BB1 cells into syngeneic mice led to the development
of mammary carcinomas that were morphologically and
immunohistochemically analogous to spontaneous tumors
(i.e., strongly positive for HER-2/neu, cytokeratins 8 and 18,
and E-cadherin). Subcutaneous injection of A17 cells into
syngeneic mice led to mesenchymal tumors that were neg-
ative for the expression of HER-2/neu, cytokeratins 8 and 18,
and E-cadherin, but positive for the expression of mesen-
chymal markers such as vimentin [27]. Carcinoma-derived
mesenchymal tumors were induced by subcutaneous injec-
tion of A17 cells. In detail, BB1 and A17 tumors were ob-
tained by subcutaneous injection of 5  105 cells into the
back of 5- to 7-week-old female FVB/neuT233 mice. Tumor
growth was monitored, and tumor size wasmeasured weekly
using calipers. The animals underwent DCE-MRI and PET
when the longest diameter of their tumors had reached 10 to
15 mm. The investigation complied with national legislation
on the care and use of laboratory animals.
Image Acquisition
DCE-MRI. Animals were examined using MRI with Gd-
DTPA-albumin as a contrast agent, and again 48 hours later
using Gd-DTPA (Magnevist; Schering, Berlin, Germany).
The mice were anesthetized by inhalation of a mixture of
air and O2 containing 0.5% to 1% isoflurane and were placed
in prone position inside a 3.5-cm-i.d. transmitter–receiver
birdcage coil. Images were acquired using a Biospec tomo-
graph (Bruker, Karlsruhe, Germany) equipped with a 4.7-T 33-
cm bore horizontal magnet (Oxford Ltd., Oxford, UK). Coronal
spin-echo and transverse multislice fast spin T2-weighted
images (TE eff = 70 milliseconds) were acquired for tumor
localization and good visualization of extratumoral tissues.
Precontrast T1 values of tumor tissues were measured using
the IR-SnapShot Flash technique (Bruker, Karlsruhe, Germany)
in a limited number of animals (n = 3) because the average
T1 value did not change significantly across the tumor tissues.
A dynamic series of transverse spoiled gradient-echo 3D
images was acquired with the following parameters: repeti-
tion time/echo time = 50/3.5 milliseconds; flip angle = 90j;
matrix size = 256  128  16; field of view = 6  3  2.4 cm3
(corresponding to 0.234  0.234 mm2 in-plane resolution
and 1.5 mm slice thickness); number of acquisitions = 1. The
acquisition time for a single 3D image was 102 seconds;
dynamic scans of 24 images were acquired at 3-second in-
tervals (total acquisition time,f 42minutes). The contrast agents
Gd-DTPA-albumin and Magnevist at 90 and 500 mmol/kg,
respectively, were injected in bolus during the interval be-
tween the first scan and the second scan. A phantom con-
taining 1 mM Gd-DTPA in saline was inserted in the field of
view and used as an external reference standard.
To calculate transendothelial permeability (Kps), the plasma
kinetics of contrast media was determined in a separate ex-
periment, as previously described [29], and carried out in a total
of six normal animals (three animals for each contrast agent).
PET image acquisition and reconstruction. FDG-PET
scanning was carried out as follows: animals were anesthe-
tized with gas anesthesia (3–5% sevoflurane and 1 l/min
oxygen) and injected with 30 MBq of FDG, at a volume of
0.1 ml, through the tail vein using an insulin syringe. The ani-
mals were subsequently allowed to wake up for the uptake
time (60 minutes) and were free to move. Residual dose was
measured to verify the dose effectively injected. Finally,
the same anesthetizing procedure was repeated to per-
form the scan. Each anesthetized animal was placed on a
scanner bed in prone position. Images were acquired with a
Small Animal PET tomograph (GE eXplore Vista DR; GE
Healthcare, Fairfield, CT) [30] for a total acquisition time of
20 minutes. Given the size of the animals, no corrections for
attenuation or scatter were performed. As the axial field of
view was 4 cm, one bed position was sufficient to cover most
of the mouse body. Once the scan was finished, the gas
anesthesia was interrupted and the animal was placed in a
recovery box with warm temperature until complete recovery.
Images were reconstructed with iterative reconstruction
on OSEM 2D (Siemens, Munich, Germany) using 2 itera-
tions and 32 subsets after Fourier rebinning. The voxel
dimensions of the reconstructed images were 0.38  0.38 
0.77 mm3. The scan was considered positive if areas of
increased FDG uptake were present in sites consistent with
the site of injection.
Computed tomography image acquisition and computed
tomography PET registration. Computed tomography (CT)
scanning was performed using a dedicated small animal CT
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scanner (GE eXplore Locus), and mice were anesthetized
analogously to PET acquisitions. CT images were recon-
structed using filtered backprojection, and the resulting voxel
dimensions were 0.18  0.18  0.18 mm3. To perform PET
and CT image registration, at least four molecular sieves
soaked with FDG were placed around the animal as reference
points, and rigid body transformation was calculated to fuse
PET and CT images. Image registration and fusion were ob-
tained using a dedicated software (MicroView; GEHealthcare).
Image Analysis
Image selection. To comparatively map vascular perfusion
and FDG uptake, we selected roughly corresponding FDG-
PET and MRI sections using the procedure described in
Figure 1. The MRI images shown were obtained by pixel-
by-pixel subtraction of the third postcontrast image from the
precontrast image. Gd-DTPA (a low-molecular-weight con-
trast agent) was chosen for this MRI-PET comparative
analysis to approximate the distribution of small molecules
such as FDG. We examined early enhancement (third of
30 acquisitions) on the assumption that, in later phases, the
contrast agent reaches nonvascularized regions by convec-
tion [31], thus compromising a clear discrimination between
regions with high and low vessel densities.
FDG-PET of high and low vascular regions. High-vascularization
and low-vascularization regions of interest (ROI) were chosen
manually on MRI subtraction images by picking regions that
exhibited high and low enhancement, respectively (Figure 1).
The signal intensities of ROI were calculated and normalized
with respect to the signal intensity of the external reference
standard to obtain comparable values of signal enhancement.
The same regions were identified in roughly corresponding
FDG-PET sections. The FDG uptake of these regions was
calculated and normalized with respect to the mean value of
the liver, using tumor-to-nontumor ratio (T/N) [32].
Comparative analysis of the vascular perfusion of the
epithelial and stromal compartments. To find vascular dif-
ferences between tumor epithelial and stromal compart-
ments, MRI signal enhancement of manually drawn ROI
covering the pericapsular region or tumor core was mea-
sured on images obtained by subtracting the most enhanced
postcontrast image (3rd for Gd-DTPA MRI or 24th for Gd-
DTPA-albumin MRI) from the precontrast image of the same
section. Ratios of values from the pericapsular region and
tumor core were calculated accordingly. Three contiguous
sections per tumor, including the one previously selected,
were analyzed.
Comparative analysis of FDG uptake and vascular perfusion
in carcinoma and mesenchymal tumors. An ROI drawn to
encompass the whole tumor made it possible to obtain the
dynamics of signal enhancement and concentration–time
curves for each sample. Vascular perfusion was evaluated
by the mean concentration value of Gd-DTPA obtained
during dynamic scanning. Following previously published
protocols [33], from the time dependence of the contrast
agent concentration, we evaluated the average Kps of the
tumors for both Gd-DTPA and Gd-DTPA-albumin [29].
Semiquantitative analysis of FDG uptake was performed
by drawing the volume of interest (VOI) to encompass the
whole tumor and by drawing a background VOI to obtain T/N
values. For background on sections covering the liver, a VOI
was drawn inside the parenchyma in each animal scan. The
mean and maximal voxel values inside each VOI were eval-
uated accordingly.
Figure 1. Selection and matching of coarsely corresponding Gd-DTPA-MRI and FDG-PET tumor sections. Each tumor underwent MRI and FDG-PET analysis. For
BB1 tumors, CT images were also acquired and coregistered with FDG-PET using at least four spatial markers as reference (cyan arrowheads). One MRI
transverse slice per tumor was chosen. The MRI geometric multislice grid was positioned on the coronal view of PET (or CT-PET– registered) acquisitions and
used as spatial reference to identify roughly corresponding transverse tumor sections. MRI images were obtained on pixel-by-pixel subtraction of the third
postcontrast and the last precontrast dynamic image (see Materials and Methods). For each tumor, two to four ROI (blue frames) were placed on high- and low-
enhanced regions of MRI images, and corresponding ROI were identified in CT-PET and/or PET sections. The values of MRI enhancement were normalized with
respect to the signal intensity of the reference standard. The values of FDG uptake were normalized with respect to the mean value of the liver.
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Statistical Analysis
The statistical significance of the differences in MRI signal
enhancement between the tumor periphery and the tumor
core for each tumor was evaluated using paired t-test.
The statistical significance of the different parameters
was evaluated using two-tailed unequal-variance t-test. P <
.05 was considered statistically significant.
Postmortem Analysis
Histologic analysis. Tumors excised from sacrificed mice
were fixed in zinc fixative, dehydrated, cut in half trans-
versally, and embedded in paraffin wax. The halves were
blocked and processed separately, with the cut edge ulti-
mately facing the microtome surface. Two consecutive sec-
tions were taken from the face of each block, and then
additional sections were taken at 100-mm intervals as far
as roughly 1 mm into each block. Sections (5 mm) were cut on
a rotary microtome and placed on polylysine-coated slides
for morphologic analysis.
The sections obtained were in planes corresponding
approximately to those used in MRI and PET evaluations.
Vessel immunostaining. Half of each of the tumor samples
was fixed in paraformaldeyde (4%) and frozen. Endothelial
cells of three sections per tumor were immunostained with
anti-CD31–specific antibody (BD PharMingen, San Diego,
CA) to visualize their vascular network. Specimens were ex-
amined with a Zeiss LSM 510 confocal microscope (Zeiss,
Oberkachen, Germany) equipped with argon (488 nm) and
helium/neon (543 nm) excitation beams.
Results
Highly Vascularized Regions in Tumors Exhibit Low
FDG Uptake
Using the procedure described in Figure 1, we matched
roughly corresponding Gd-DTPA-MRI and FDG-PET tu-
mor sections of four BB1 carcinomas and four A17 mesen-
chymal tumors.
The signal enhancement of highly vascularized regions
was 0.198 ± 0.07 for BB1 tumors and 0.65 ± 0.3 for A17
tumors. The signal enhancement of poorly vascularized
regions was 0.062 ± 0.035 for BB1 tumors and 0.19 ± 0.13
for A17 tumors (P < .01 for both tumor histotypes).
Considering all the eight tumors together, we found that
highly vascularized regions exhibited significantly lower FDG
uptake than regions with low vascularization (T/N: 1.37 ±
0.39 vs 1.99 ± 0.55, P < .005) (Figure 2). Considering the
single histotypes separately, BB1 tumors showed a greater
difference between FDG uptake in high-MRI–enhanced
and low-MRI–enhanced regions (T/N: 1.35 ± 0.48 vs
2.1 ± 0.60, P < .05) than A17 tumors (T/N: 1.38 ± 0.40
vs 1.80 ± 0.45, P = .13), suggesting a greater heteroge-
neity of MRI and FDG maps in carcinomas than in the mes-
enchymal tumor histotype.
Differential Spatial Distribution of Gd-DTPA and FDG
Uptake in Pericapsular Region and Intratumoral
Connectival Septa
The vascular supply in carcinomas is provided by tumor
stroma. We were therefore interested in assessing whether
regions with a high-vascular/low-FDG uptake pattern corre-
sponded to the stromal compartment in carcinomas. MRI
analysis was performed on five tumors. We found that the
enhancement of MRI signal intensity was significantly
higher at the tumor periphery than at the tumor core, with
both Gd-DTPA (1.25 ± 0.24-fold, P < .01) and Gd-DTPA-
albumin (2.08 ± 1.67-fold, P < .01) partly overlapping with
the highly vascularized tumor capsule [34] along with a mod-
erately vascularized subcapsular layer (Figure 3, A–D). In-
side the tumor parenchyma, contrast enhancement roughly
matched large intratumoral stromal septa (Figure 3, B and
D). In contrast, FDG uptake was observed inside the tumor
parenchyma, which was mainly composed of epithelial cells,
except in correspondence with necrotic areas (Figure 3, C and
E ), and showed discontinuities in correspondence with large
intratumoral connectival septa (Figure 3, D and F ).
With the aim of investigating whether vascular differences
between tumor rim and tumor core are typical of carcinomas
or are independent of tumor histotype, we performed the
same analysis on A17 tumors, which were composed of the
homogeneous parenchyma of mesenchymal cells and did
not show a distinguishable stromal capsule, except where
tumor parenchyma invaded the cutis (Figure 3, G– I ). MRI
analysis was performed on five tumors. Although the signal
enhancement induced by MRI tracers was higher at the tu-
mor periphery than at the core with both Gd-DTPA (1.20 ±
0.35–fold) and Gd-DTPA-albumin (1.08 ± 0.42–fold), the
differences were not statistically significant (P > .05).
Differential Spatial Distribution of Gd-DTPA and FDG
Uptake in Spontaneous Tumors
To further exploit the reciprocal pattern of vascular per-
fusion and glucose metabolism, we performed PET and
Figure 2. Comparative analysis of MRI enhancement in carcinomas (BB1)
and mesenchymal tumors (A17). In both BB1 and A17 tumors, FDG uptake
proved higher in high-MRI– than in low-MRI–enhanced regions.
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Gd-DTPA analysis on carcinomas that spontaneously arose
in four HER-2 transgenic mice.
We also applied a more precise procedure to select the
corresponding PET and MRI sections: After PET scans, the
molecular sieves placed around the animals as reference
points were replaced by pieces of blotting paper embedded
with vegetable oil detectable on MR images. By rigid trans-
formation, a better alignment of MRI and PET sections was
obtained, despite unavoidable changes in animal position
due to the different animal couch. In this tumor model, large
necrotic areas, which did not appreciably enhance on both
PET and MRI, were revealed. Viable tumor tissues sur-
rounding large unenhancing areas evidenced a comple-
mentary amount of FDG and Gd-DTPA uptake, with regions
of higher and lower FDG consumption characterized, respec-
tively, by lower and higher signal intensities on the early phase
of contrast MRI enhancement (Figure 4).
Carcinoma-Derived Mesenchymal Tumors (A17) Exhibit
Higher Vascular Perfusion But Lower FDG Uptake Than
Syngeneic Carcinomas (BB1)
We observed that a complementary pattern of vascular
perfusion and FDG uptake comparing BB1 carcinomas and
A17 mesenchymal tumors was reproduced.
MRI enhancement in A17 tumors, which was measured
by taking the entire tumor section into account, was signifi-
cantly higher than that in BB1 tumors (Table 1). In contrast,
FDG uptake by A17 tumors proved significantly lower than
that by BB1 tumors, taking both mean and maximal values
into consideration (Table 1).
Several authors have investigated the correlations be-
tween vascular parameters and FDG uptake in human
tumors, with contrasting results: DCE-MRI–assessed Kps
has been reported to be directly or inversely correlated with
glucose metabolism [35,36]. In this study, we evaluated the
Figure 3. Mapping of perfusion and metabolic patterns in transplanted tumors. On BB1 tumors, third postcontrast minus precontrast images after Gd-DTPA
injection showed enhancement at the tumor periphery, typical of carcinomas (A), or, less frequently, in restricted regions of the intratumoral parenchyma (B). On
histologic analysis, the peripheral areas of enhancement matched peritumoral capsule and an epithelial subcapsular layer. MRI enhancement showed
discontinuities in correspondence with necrotic areas (C) and, inside the tumor parenchyma, roughly matched large intratumoral stromal septa (D; arrowhead). The
surrounding epithelial parenchyma showed progressively lower cellular density as distance from intratumoral connectival septa increased. FDG uptake showed a
complementary pattern to Gd-DTPA distribution (E and F). Corresponding CT images were overlapped on PET images to allow tumor delineation. On A17 tumors,
third postcontrast minus precontrast images after Gd-DTPA injection showed evident—although inhomogeneous—intratumoral enhancement (G). On histologic
analysis (H), tumor parenchyma proved homogeneous from the periphery to the core with only a small focus of necrosis (black arrowhead) and did not exhibit a
stromal capsule except at the external side, where tumor invaded the skin (cyan arrowheads). FDG uptake exhibited an inhomogeneous pattern (I) that is roughly
complementary to MRI tracer enhancement.
904 Metabolic/Vascular Complementaries in Tumors Galie` et al.
Neoplasia . Vol. 9, No. 11, 2007
Kps of A17 and BB1 tumors using DCE-MRI with both extra-
vascular (Gd-DTPA) and intravascular (Gd-DTPA-albumin)
contrast agents, and we investigated its correlation with FDG
uptake. In accordance with previous observations [27,37],
A17 tumors exhibited significantly (P < .05) higher Kps than
BB1 tumors (Table 1) with Gd-DTPA-albumin. This result was
confirmed by DCE-MRI with GD-DTPA, although statistical
significance was weak (P = .07). It was consistent with
Figure 4. Mapping of perfusion and metabolic pattern on spontaneous carcinomas. Precontrast (A), early postcontrast (B), T2-weighted (C), and FDG-PET (D)
corresponding sections of a spontaneous breast carcinoma. External reference points (white arrows) were used to obtain better alignment between MRI and PET
scan. A large hemorrhagic necrotic area was appreciable in a T2 image (asterisks), which did not enhance on postcontrast MRI and did not take up FDG. Viable
tumor tissues evidenced areas of higher and lower FDG consumption (arrowhead) revealing, respectively, lower and higher Gd-DTPA enhancement.
Table 1. Quantitative Analysis of FDG-PET and DCE-MRI Examinations.
FDG-PET DCE-MRI
T/N Mean Concentration (mM) Kps [(ml/min) per cm3]
Mean Maximal Gd-DTPA Gd-DTPA Gd-DTPA Albumin
BB1 1.94 2.63 0.59 0.021 0
2.27 2.78 NA NA NA
2.32 3.01 0.53 0.0145 0.0005
2.46 3.50 0.60 0.017 0
2.08 2.77 0.47 0.017 0.0005
2.19 2.93 NA NA NA
Mean ± SD 2.20 ± 0.20 2.97 ± 0.33 0.55 ± 0.06 0.017 ± 0.002 0.00025 ± 0.0003
A17 1.35 1.85 NA NA NA
1.91 2.77 0.97 0.033 0.0018
1.73 2.25 0.71 0.028 0.0015
1.54 2.37 0.91 0.047 0.0007
1.93 2.54 0.60 0.017 0.0017
1.64 2.10 NA NA 0.0009
Mean ± SD 1.69 ± 0.22 2.31 ± 0.32 0.80 ± 0.17 0.03 ± 0.01 0.0013 ± 0.0005
Statistical significance (P) .003 .009 .003 .07 .006
For FDG-PET analysis, we report the mean and maximal T/N values of the VOI, which encompassed the whole section of the tumors. For DCE-MRI, the mean
concentration values of Gd-DTPA over the acquisition time are reported, and Kps was obtained from the two-compartment kinetic analysis of both Gd-DTPA and
Gd-DTPA-albumin enhancement curves. Statistical significance refers to the comparison between the BB1 and A17 tumor groups.
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histologic features of A17 vessels, which frequently ap-
peared smaller in size but had a higher surface/volume ratio
than BB1 vessels (Figure 5).
Intragroup analysis (i.e., only of the A17 group, or of the
BB1 group) showed no statistically significant correlation be-
tween FDG uptake and perfusion parameters.
Both Carcinomas and Mesenchymal Tumors Exhibit
Enhanced Metabolism with Respect to Nontumor Tissues
FDG-PET is being used in clinical practice as a tool for
tumor diagnosis, on the assumption that tumors exhibit an
inherently enhanced glucose metabolism with respect to
surrounding normal tissues. Our results confirmed this as-
sumption, as FDG uptake values in carcinomas and mes-
enchymal tumors proved higher than the mean values of
nontumor reference tissues (liver), whether the entire tu-
mor section (Table 1; BB1, T/N = 1.94–2.46; A17, T/N =
1.35–1.93), or the most highly FDG-enhanced regions
(BB1, T/N = 1.18–3.07; A17, T/N = 1.41–2.53), or the re-
gions with the lowest FDG enhancement (BB1, T/N = 0.83–
1.77; average = 1.35 ± 0.41; A17, T/N = 0.85–1.94;
average = 1.38 ± 0.40) were taken into account.
Discussion
Our results involve pressing questions in tumor biology and
clinical oncology. We demonstrated a complementary spatial
pattern of vascular perfusion and glucose metabolism in
tumors. After we had finished this study, an in vivo mapping
study by Raman et al. [38] demonstrated a complementary
pattern of vascular volume and hypoxia in a model of pros-
tate cancer. Their data are consistent with ours, as it is well
known that hypoxia enhances glucose uptake through the
opening of GLUT-1 transporters [39].
Vascular/Metabolic Reciprocity within Carcinomas
We showed that this reciprocity is greater in carcinomas
than in mesenchymal tumors, and that it was associated with
the spatial distribution of the epithelial and stromal compart-
ments. In transplanted carcinomas (BB1), vascular supply
proved higher at the tumor periphery, as shown for human
cancers [40], partly corresponding to the stromal capsule,
than inside the tumor. In contrast, FDG uptake proved higher
in the middle of non-necrotic tumor parenchyma, where
epithelial tissue was prevalent. Where large intratumoral
connectival septa were observed, the pattern of DCE-MRI
and FDG uptake was inverted. Thus, we provide in vivo
evidence of an intriguing aspect of epithelial–stromal inter-
action in carcinomas showing vascular and metabolic reci-
procity between these two tumor compartments. This
complementary pattern can be explained by recent evidence
of synergistic metabolic interaction between epithelial and
mesenchymal cell populations. Tumor blood vessels are dis-
tributed mainly within the stromal compartment, and the role
of stromal cells in promoting their generation and organi-
zation has been extensively examined. As tumors grow,
epithelial cells are found progressively farther from blood
vessels as the distance from intratumoral connectival septa
increases, and scarcity of oxygen contributes to the switch-
ing of their metabolism toward anaerobic processes, which
ultimately produce lactate. Abundant oxygen supply to tumor-
associated stromal cells allows them not only to produce
Figure 5. Histologic analysis of tumor vessels. On CD31 immunostaining, vessels of A17 tumors were more numerous and uniformly distributed inside the tumor
parenchyma, but were smaller in size (A–C) than vessels of BB1 (D–F), which were mainly found at the tumor periphery. Because BB1 vessels are only restricted
to occasionally stromal regions of the tumor, the reported images are representative only of the highly vascularized area (stromal septa). The higher surface/
volume ratio appeared consistent with the significantly higher Kps of A17 tumors compared with BB1 tumors (Table 1).
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energy aerobically but also to recycle the lactate released by
cancer cells. Thus, the epithelial and stromal populations of
growing tumors can be viewed as two parts of a functional
domain with genuine metabolic cooperation between anaero-
bic and aerobic compartments [10,41].
Vascular/Metabolic Reciprocity between Epithelial and
Mesenchymal Histotypes
The complementarities observed between epithelial and
mesenchymal compartments of the same carcinomas were
again found between epithelial and mesenchymal tumor
models raised by the subcutaneous injection of cell lines
derived from the same mammary carcinoma. A17 tumors
exhibited a higher mean MRI enhancement and a lower
mean FDG uptake than BB1 carcinomas. The shift of carci-
nomas toward a mesenchymal phenotype is a matter of
concern in clinical oncology, as it represents a poor prog-
nostic factor [42]. In addition, the scarcity of oxygen, which is
inherent in carcinomas, can provide a decisive contribution to
the generation of tumor-promoting or tumorigenic mesen-
chymal populations. Stromal cells at the invasive tumor front
are directly activated by anoxia, as occurs physiologically in
wound-healing processes [43]. Normal fibroblasts respond-
ing to anoxia exhibit features of malignant phenotype be-
cause their proliferation increases and triggers proangiogenic,
antiapoptotic, locomotor, and invasive programs [41,44–47].
In any case, recent studies on experimental models of HER-2/
neu tumors demonstrated that the possibility of developing
into mesenchymal tumors is inherent in carcinomas. Hill et al.
[23] showed that the neoplastic epithelial compartment indu-
ces aberrant evolution of genetically altered stromal mesen-
chyme. Moody et al. [25] found that mesenchymal tumors can
spontaneously arise as recurrences after the regression of
primary tumors in an inducible HER-2/neumodel of carcinoma
[48]. Knutson et al. [24] and Moody et al. [25] showed that
anti–HER-2/neu–specific immune response can select neu-
negative mammary tumors with mesenchymal phenotype.
This evidence greatly enhances the clinical significance of
experimental models of carcinoma-derived mesenchymal tu-
morigenic cells.
Several authors have investigated the correlations be-
tween vascular parameters and FDG uptake in human tu-
mors, providing controversial results [35,36]. In accordance
with previous observations [27,37], here we found that A17
tumors exhibited significantly higher Kps than BB1 tumors.
However, intragroup correlation between FDG uptake and
MRI-measured Kps in our experimental model did not reach
statistical significance. This probably reflects the fact that
the relationship between glucose metabolism and blood
supply is affected by a number of (morphologic or biochem-
ical) factors [49,50].
Potential Clinical Implications
Given that in vivo assessment of glucose metabolism by
FDG-PET is being used in clinical practice for tumor diagnosis/
grading and therapy monitoring, our results highlight the
risk of underestimating the malignity of carcinomas that
are highly vascularized and/or exhibit any traits of mesen-
chymalization, such as desmoplasia [51] or epithelial–
mesenchymal transition [52]. In particular, lower glucose
consumption of the stromal compartment could make FDG-
based pretreatment tumor delineation difficult. The exact def-
inition of tumor extension has a profound impact on tumor
local control, which justifies the enormous expenditure in-
volved in multiple noninvasive imagings performed in clinical
practice. In this respect, FDG distribution is proposed not
only for lymph node staging but also to delineate gross tumor
volume for planning radiotherapy treatments [6,7], but only
occasionally is delineation based on FDG-PET compared
with pathological examination [8], and studies with similar
design are awaited [9]. Our findings alert to the risk that only
part of the tumor could be treated in some cases because it
appears that such approach could limit therapy to the lowest
vascularized regions, adding biologic consideration to the
opinion that PET-directed tumor volume contouring is not
ready for clinical practice without further technological
improvements in imaging specificity/sensitivity [53].
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